Clinical efficacy of becaplermin (rhPDGF-BB) gel

American Journal of Surgery

Volumn 176, Issue 2 A, 1998, Pages 74S-79S

  Wieman, T Jeffery ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT PLATELET DERIVED GROWTH FACTOR;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC FOOT; DRUG EFFICACY; FOOT ULCER; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME; WOUND HEALING;

EID: 0031681266     PISSN: 00029610     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9610(98)00185-8     Document Type: Article

References (21)

1. World Health Organization. The World Health Report 1997: Conquering Suffering, Enriching Humanity. Geneva, Switzerland: World Health Organization, 1997.
2. Sedory Holzer SE, Camerota A, Martens L, et al. Costs and duration of care for lower extremity ulcers in patients with diabetes. Clin Ther. 1998;20:169-181.
3. Reiber GE. Diabetic foot care: financial implications and practice guidelines. Diabetes Care. 1992;15(suppl 1):29-31.
4. Apelqvist J, Ragnarson-Tennvall G, Larsson J, Persson U. Long-term costs for foot ulcers in diabetic patients in a multidisciplinary setting. Foot Ankle Int. 1995;16:388-394.
5. Centers for Disease Control and Prevention. National Diabetes Fact Sheet: National Estimates and General Information on Diabetes in the United States. Atlanta: Centers for Disease Control and Prevention, 1997.
6. Bild DE, Selby JV, Sinnock P, et al. Lower-extremity amputation in people with diabetes: epidemiology and prevention. Diabetes Care. 1989;12:24-31.
7. Fylling CP. Conclusions. Diabetes Spectrum. 1992;5:358-359.
8. Reiber GE, Boyko EJ, Smith DG. Lower extremity foot ulcers and amputations in diabetes. In: Harris MI, Cowie CC, Reiber G, et al., eds. Diabetes in America. Washington, DC: US Government Printing Office, 1995:409-428.
9. Kiritsy CP, Lynch AB, Lynch SE. Role of growth factors in cutaneous wound healing: a review. Crit Rev Oral Biol Med. 1993; 4:729-760.
10. Greenhalgh DG. The role of growth factors in wound healing. J Trauma. 1996;41:159-167.
11. Robson MC. The role of growth factors in the healing of chronic wounds. Wound Repair Regen. 1997;5:12-17.
12. Robson MC. Exogenous growth factor application effect on human wound healing. Prog Dermatol. 1996;30:1-7.
13. Steed DL, The Diabetic Ulcer Study Group. Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity diabetic ulcers. J Vasc Surg. 1995;21: 71-81.
14. Wieman TJ, Smiell JM, Su Y. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with nonhealing diabetic ulcers: a phase III, randomized, placebo-controlled, double-blind study. Diabetes Care. 1998;21:822-827.
15. The National Pressure Ulcer Advisory Panel. Pressure ulcers prevalence, cost and risk assessment: consensus development conference statement. Decubitus. 1989;2:24-28.
16. Dermal wounds: pressure sores. Philosophy of the IAET. J Enterostomal Ther. 1988;15:4-17.
17. Walsh CH. A healed ulcer: what now? Diabetic Med. 1996;13: S58-S60.
18. Leaper DJ. The wound healing process. In: Turner TD, Schmidt RJ, Harding KG, eds. Advances in Wound Management. Chichester, England: John Wiley and Sons, 1985:7-16.
19. Mast BA. The skin. In: Cohen IK, Diegelmann RF, Lindblad WJ, eds. Wound Healing Biochemical and Clinical Aspects. Philadelphia: W.B. Saunders Company, 1992:344-355.
20. d'Hemecourt PA, Smiell JM, Karim MR. Effect of sodium carboxymethylcellulose aqueous-based gel in patients with non-healing, lower extremity diabetic ulcers. Diabetic Care, (in press).
21. Smiell JM, Becaplermin Studies Group. Clinical safety of becaplermin (rhPDGF-BB) gel. Am J Surg. 1998;176(Suppl 2A):68S-73S.